Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol.
Propranolol, a beta-adrenergic blocker agent widely used in a number of cardiovascular disorders, increases plasminogen activator (PA) activity in confluent bovine aortic endothelial cells (BAEC). This effect is time and dose dependent (10-100 microM). Hybridization studies with specific cDNA showed that propranolol was able to induce an increase in urokinase mRNA expression in a dose and time dependent manner. The propranolol effect seems to be specific for urokinase mRNA, because it does not affect a-actin mRNA expression. Cycloheximide, similarly to propranolol, also increases urokinase mRNA, indicating that the gene expression may be regulated by some rapidly turning over protein. When compounds were used in combination, a superinduction phenomenon was observed.
Peracchia
F
F
Consorzio Mario Negri Sud, Milano, Italy.
Polentarutti
N
N
Colotta
F
F
Mussoni
L
L
D000818:Animals; D001011:Aorta; D002417:Cattle; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D015342:DNA Probes; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000201:enzymology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D009693:Nucleic Acid Hybridization; D011433:Propranolol / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics*; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics*
D015342:DNA Probes; D012333:RNA, Messenger; D003513:Cycloheximide; D011433:Propranolol; D014568:Urokinase-Type Plasminogen Activator